FATE

Fate Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · fatetherapeutics.com

$1.80

Mkt Cap $209.3M

52w Low $0.91 86.4% of range 52w High $1.94

50d MA $1.29 200d MA $1.18

P/E (TTM) -1.3x

EV/EBITDA -1.2x

P/B 0.9x

Debt/Equity 0.4x

ROE -65.8%

P/FCF -1.0x

RSI (14) —

ATR (14) —

Beta 2.24

50d MA $1.29

200d MA $1.18

Avg Volume 1.5M

About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 26, 2026	AMC	-0.27	-0.27	+0.0%	1.56	-0.6%	-5.1%	-3.8%	-12.2%	-7.1%	-11.5%	-27.6%	—
Nov 13, 2025	AMC	-0.29	-0.27	+6.9%	0.99	-0.7%	-2.9%	-1.9%	+2.8%	+5.8%	+0.8%	+12.9%	—
Aug 12, 2025	AMC	-0.35	-0.29	+17.1%	0.94	+1.5%	+20.7%	+14.3%	+16.4%	+28.2%	+21.8%	+8.9%	—
May 13, 2025	AMC	-0.39	-0.32	+17.9%	1.00	+5.0%	-4.0%	+1.0%	+7.0%	+22.0%	+25.0%	+40.0%	—
Mar 5, 2025	AMC	-0.44	-0.31	+29.5%	0.91	+0.5%	+14.9%	+11.6%	+2.4%	+6.1%	+11.6%	-16.8%	—
Nov 12, 2024	AMC	-0.42	-0.40	+4.8%	2.38	+2.9%	-8.8%	-12.6%	-15.1%	-4.6%	-8.4%	-18.9%	—
Aug 13, 2024	AMC	-0.47	-0.33	+29.8%	3.34	+1.2%	-2.1%	+1.5%	+1.8%	+8.7%	+9.9%	+12.0%	—
May 9, 2024	AMC	-0.47	-0.47	+0.0%	3.90	-1.3%	+4.6%	+6.4%	+8.2%	+8.7%	+6.2%	-1.0%	—
Feb 26, 2024	AMC	-0.57	-0.45	+21.1%	6.95	+8.8%	+7.3%	+2.7%	+2.0%	+11.4%	+1.9%	+5.6%	—
Nov 8, 2023	AMC	-0.59	-0.46	+22.0%	2.33	+3.0%	-8.6%	-11.6%	-14.6%	-0.9%	+6.4%	-3.9%	—
Aug 8, 2023	AMC	-0.58	-0.54	+6.9%	3.53	-0.8%	-3.7%	-7.6%	-12.5%	-14.4%	-17.0%	-30.0%	—
May 3, 2023	AMC	-0.55	-0.19	+65.5%	6.32	-5.1%	-2.4%	-10.1%	-13.8%	-14.7%	-15.5%	-16.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Oct 31	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$1.29	$1.40	+8.5%	+4.7%	-2.3%	-7.8%	-15.5%	-19.4%
Oct 27	Wedbush	Upgrade	Neutral → Outperform	—	$1.65	$1.75	+6.1%	-6.1%	-9.7%	-18.8%	-21.8%	-18.2%
Oct 27	Needham	Maintains	Hold → Hold	—	$1.65	$1.75	+6.1%	-6.1%	-9.7%	-18.8%	-21.8%	-18.2%
Aug 13	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$0.94	$0.95	+1.5%	+20.7%	+14.3%	+16.4%	+28.2%	+21.8%
Jun 12	Needham	Maintains	Hold → Hold	—	$1.55	$1.50	-3.2%	-9.7%	-18.1%	-20.0%	-22.6%	-21.9%
May 14	Baird	Maintains	Neutral → Neutral	—	$1.00	$1.05	+5.0%	-4.0%	+1.0%	+7.0%	+22.0%	+25.0%
May 14	Needham	Maintains	Hold → Hold	—	$1.00	$1.05	+5.0%	-4.0%	+1.0%	+7.0%	+22.0%	+25.0%
May 14	Barclays	Maintains	Overweight → Overweight	—	$1.00	$1.05	+5.0%	-4.0%	+1.0%	+7.0%	+22.0%	+25.0%
Mar 6	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$0.91	$0.91	+0.5%	+14.9%	+11.6%	+2.4%	+6.1%	+11.6%
Mar 6	Wedbush	Maintains	Neutral → Neutral	—	$0.91	$0.91	+0.5%	+14.9%	+11.6%	+2.4%	+6.1%	+11.6%
Mar 6	Needham	Maintains	Hold → Hold	—	$0.91	$0.91	+0.5%	+14.9%	+11.6%	+2.4%	+6.1%	+11.6%
Mar 6	Stifel	Maintains	Hold → Hold	—	$0.91	$0.91	+0.5%	+14.9%	+11.6%	+2.4%	+6.1%	+11.6%
Aug 22	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$3.91	$3.96	+1.3%	-3.6%	-1.8%	-0.8%	-8.2%	-10.2%
Jun 17	Piper Sandler	Upgrade	Neutral → Overweight	—	$3.61	$3.93	+8.9%	-1.1%	-5.5%	-0.6%	+4.2%	+6.4%
May 16	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$4.24	$4.26	+0.5%	-2.4%	-8.0%	-7.8%	-12.7%	-13.9%
May 10	Wedbush	Maintains	Neutral → Neutral	—	$3.90	$3.85	-1.3%	+4.6%	+6.4%	+8.2%	+8.7%	+6.2%
May 10	BMO Capital	Maintains	Market Perform → Market Perform	—	$3.90	$3.85	-1.3%	+4.6%	+6.4%	+8.2%	+8.7%	+6.2%
May 10	Canaccord Genuity	Maintains	Buy → Buy	—	$3.90	$3.85	-1.3%	+4.6%	+6.4%	+8.2%	+8.7%	+6.2%
May 10	Piper Sandler	Maintains	Neutral → Neutral	—	$3.90	$3.85	-1.3%	+4.6%	+6.4%	+8.2%	+8.7%	+6.2%
May 6	Wedbush	Maintains	Neutral → Neutral	—	$4.06	$4.08	+0.5%	+3.9%	-4.4%	-8.9%	-3.9%	+0.5%
Apr 23	Wedbush	Maintains	Neutral → Neutral	—	$4.78	$4.79	+0.2%	-5.0%	-10.0%	-19.0%	-20.5%	-15.5%
Mar 28	BofA Securities	Maintains	Underperform → Underperform	—	$7.34	$7.27	-1.0%	+0.0%	-3.5%	-7.4%	-4.5%	-5.0%
Mar 19	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$7.04	$6.83	-3.0%	-0.6%	+5.5%	+5.5%	-6.1%	-2.4%
Feb 27	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$6.95	$7.56	+8.8%	+7.3%	+2.7%	+2.0%	+11.4%	+1.9%
Feb 27	BMO Capital	Maintains	Market Perform → Market Perform	—	$6.95	$7.56	+8.8%	+7.3%	+2.7%	+2.0%	+11.4%	+1.9%
Feb 27	Wedbush	Maintains	Neutral → Neutral	—	$6.95	$7.56	+8.8%	+7.3%	+2.7%	+2.0%	+11.4%	+1.9%
Feb 27	Barclays	Maintains	Overweight → Overweight	—	$6.95	$7.56	+8.8%	+7.3%	+2.7%	+2.0%	+11.4%	+1.9%
Feb 27	Oppenheimer	Maintains	Perform → Perform	—	$6.95	$7.56	+8.8%	+7.3%	+2.7%	+2.0%	+11.4%	+1.9%
Nov 20	Mizuho	Maintains	Buy → Buy	—	$2.43	$2.44	+0.4%	+7.0%	+0.8%	-1.6%	-2.9%	-6.2%
Nov 13	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$2.06	$2.01	-2.4%	-3.4%	+12.1%	+20.4%	+15.5%	+18.0%
Nov 9	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$2.33	$2.40	+3.0%	-8.6%	-11.6%	-14.6%	-0.9%	+6.4%
Nov 9	BMO Capital	Maintains	Market Perform → Market Perform	—	$2.33	$2.40	+3.0%	-8.6%	-11.6%	-14.6%	-0.9%	+6.4%
Nov 9	Wedbush	Maintains	Neutral → Neutral	—	$2.33	$2.40	+3.0%	-8.6%	-11.6%	-14.6%	-0.9%	+6.4%
Sep 7	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$2.60	$2.55	-1.9%	-5.0%	-4.6%	-6.2%	-2.3%	-8.1%
Aug 16	Truist	Maintains	Hold → Hold	—	$2.93	$2.90	-1.0%	-4.8%	-5.1%	-5.1%	-6.8%	-9.2%
Aug 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$3.40	$3.37	-0.9%	-4.1%	-9.1%	-11.2%	-13.8%	-17.9%
Aug 10	Barclays	Maintains	Overweight → Overweight	—	$3.40	$3.37	-0.9%	-4.1%	-9.1%	-11.2%	-13.8%	-17.9%
Aug 9	BMO Capital	Maintains	Market Perform → Market Perform	—	$3.53	$3.50	-0.8%	-3.7%	-7.6%	-12.5%	-14.4%	-17.0%
Aug 9	EF Hutton	Maintains	Buy → Buy	—	$3.53	$3.50	-0.8%	-3.7%	-7.6%	-12.5%	-14.4%	-17.0%
May 5	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$6.17	$6.28	+1.8%	-7.9%	-11.7%	-12.6%	-13.5%	-14.7%
May 4	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$6.32	$6.00	-5.1%	-2.4%	-10.1%	-13.8%	-14.7%	-15.5%
May 4	Stifel	Maintains	Hold → Hold	—	$6.32	$6.00	-5.1%	-2.4%	-10.1%	-13.8%	-14.7%	-15.5%
Mar 2	Citigroup	Maintains	Buy → Buy	—	$6.09	$6.10	+0.2%	+0.0%	+0.3%	-4.4%	-6.7%	-7.7%
Mar 1	EF Hutton	Maintains	Buy → Buy	—	$6.12	$6.16	+0.7%	-0.5%	-0.5%	-0.2%	-4.9%	-7.2%
Jan 24	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$5.55	$5.42	-2.3%	-2.2%	-2.7%	-4.5%	+6.7%	+3.2%
Jan 9	Goldman Sachs	Maintains	Sell → Sell	—	$4.24	$4.32	+1.9%	+24.3%	+29.5%	+34.9%	+38.2%	+27.4%
Jan 6	Cowen & Co.	Downgrade	Outperform → Market Perform	—	$11.00	$4.38	-60.2%	-61.5%	-52.1%	-50.1%	-48.0%	-46.7%
Jan 6	BMO Capital	Downgrade	Outperform → Market Perform	—	$11.00	$4.38	-60.2%	-61.5%	-52.1%	-50.1%	-48.0%	-46.7%
Jan 6	Stifel	Downgrade	Buy → Hold	—	$11.00	$4.38	-60.2%	-61.5%	-52.1%	-50.1%	-48.0%	-46.7%
Jan 6	BofA Securities	Downgrade	Buy → Underperform	—	$11.00	$4.38	-60.2%	-61.5%	-52.1%	-50.1%	-48.0%	-46.7%

Recent Filings

8-K

Fate Therapeutics, Inc. -- 8-K Filing

Fate Therapeutics is advancing its iPSC-derived cellular immunotherapy pipeline toward Phase 2 trials, signaling progress in clinical development that could validate its off-the-shelf cell therapy platform's therapeutic potential.

Feb 26

Data updated apr 25, 2026 8:26am · Source: massive.com